Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)

Change from Baseline in Erythrocyte Sedimentation Rate (ESR) Over Time

Time frame: Baseline up to Month 6

Time to Discontinuation

Time frame: Baseline up to Month 6

Percentage of Participants With Monotherapy Versus Combination Therapy with Methotrexate

Time frame: Baseline up to Month 6

Percentage of Participants With Systemic Symptoms at Baseline Versus Without Systemic Symptoms at Baseline

Time frame: Baseline

Percentage of Participants with Remission (DAS28 <2.6) and Low Disease Activity (DAS28 </= 3.2) After 3 Months of Treatment

Time frame: Month 3

Change From Baseline in DAS28 Over Time

Time frame: Baseline up to Month 6

Change From Baseline in C-Reactive Protein (CRP) Over Time

Time frame: Baseline up to Month 6

Percentage of Participants With Discontinuations Due to Lack of Efficacy

Time frame: Baseline up to Month 6

Percentage of Participants With Adverse Events (AEs) Or Serious AEs (SAEs)

Time frame: Baseline up to Month 6